Physician profile
Thomas E Esposito
NPI 1902946627
$2,889.35
in general payments reported to CMS, 2019-2025
26 companies · $916 in 2025
The $916 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $148 · 2021: $106 · 2022: $305 · 2023: $501 · 2024: $689 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.69 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $485.09 | 2022-2025 | |
| Glaxosmithkline, LLC. | $339.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $260.76 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $223.19 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $163.15 | 2019-2025 | |
| Exact Sciences Corporation | $160.68 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $134.72 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $43.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.13 | 2019 | |
| Boston Scientific Corporation | $24.52 | 2025 | Watchman Access System |
| Abbott Laboratories | $23.98 | 2025 | Freestyle Libre 2 |
| Allergan, INC. | $23.00 | 2020 | |
| Si-Bone, INC. | $21.74 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.72 | 2025 | Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $21.53 | 2024 | Xarelto |
| Almatica Pharma LLC | $19.12 | 2023 | Gralise |
| Biohaven Pharmaceuticals, INC. | $17.98 | 2021 | |
| Nevro Corp. | $17.45 | 2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.27 | 2023 | Xifaxan |
| Genentech USA, INC. | $16.00 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.62 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $13.67 | 2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.